Entellus Medical, Inc. (ENTL) Raised to Buy at BidaskClub
BidaskClub upgraded shares of Entellus Medical, Inc. (NASDAQ:ENTL) from a hold rating to a buy rating in a research report report published on Saturday morning.
A number of other brokerages also recently weighed in on ENTL. Zacks Investment Research raised shares of Entellus Medical from a sell rating to a hold rating in a report on Tuesday, August 1st. Piper Jaffray Companies reissued a buy rating on shares of Entellus Medical in a report on Wednesday, July 12th. Canaccord Genuity downgraded shares of Entellus Medical from a buy rating to a hold rating and reduced their price target for the company from $22.00 to $18.00 in a report on Thursday, May 4th. ValuEngine raised shares of Entellus Medical from a strong sell rating to a sell rating in a report on Friday, June 2nd. Finally, William Blair reissued an outperform rating on shares of Entellus Medical in a report on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. Entellus Medical currently has a consensus rating of Hold and an average price target of $21.71.
Shares of Entellus Medical (ENTL) opened at 17.70 on Friday. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $22.63. The stock has a 50 day moving average of $17.16 and a 200 day moving average of $14.93. The company’s market cap is $449.07 million.
Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.03. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.87 million. During the same period in the prior year, the company posted ($0.27) earnings per share. Entellus Medical’s quarterly revenue was up 18.0% on a year-over-year basis. On average, equities analysts anticipate that Entellus Medical will post ($1.62) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/23/entellus-medical-inc-entl-raised-to-buy-at-bidaskclub.html.
A number of hedge funds have recently modified their holdings of ENTL. Laurion Capital Management LP acquired a new position in Entellus Medical during the first quarter worth approximately $1,713,000. Royce & Associates LP increased its position in Entellus Medical by 288.4% in the first quarter. Royce & Associates LP now owns 167,000 shares of the medical technology company’s stock worth $2,305,000 after buying an additional 124,000 shares during the last quarter. Cortina Asset Management LLC increased its position in Entellus Medical by 22.6% in the first quarter. Cortina Asset Management LLC now owns 412,323 shares of the medical technology company’s stock worth $5,690,000 after buying an additional 75,879 shares during the last quarter. William Blair Investment Management LLC increased its position in Entellus Medical by 1,017.0% in the first quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock worth $5,387,000 after buying an additional 355,388 shares during the last quarter. Finally, Blair William & Co. IL acquired a new position in Entellus Medical during the first quarter worth approximately $1,229,000. 67.61% of the stock is owned by hedge funds and other institutional investors.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.